{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:57:41Z","timestamp":1791568661646,"version":"4.3.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"\n Background:<\/jats:title>\n Pyrazinamide is one of the antitubercular drugs used for 2 months in the intensive phase. One of the adverse effects of pyrazinamide is hyperuricemia, with a symptom of arthralgia. This study aims to analyze the incidence of hyperuricemia and arthralgia and their causality in pulmonary tuberculosis (TB) patients undergoing treatment in the intensive phase.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n It was an analytic observational study with a prospective cohort design. Three ml of blood from each pulmonary TB patient was withdrawn to examine uric acid levels before and after 2 months of treatment with pyrazinamide. The Wilcoxon test was used to analyze changes in uric acid levels and the Chi-square test to analyze the association between uric acid levels and arthralgia. Naranjo algorithm is used to analyze the causality of hyperuricemia.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Twenty pulmonary TB patients met the inclusion criteria in this study. Eight out of 12 (60%) TB patients showed uric acid levels \u22657 mg\/dl and 8 of them (66.6%) showed symptoms of arthralgia. The median uric acid level increased significantly before (5.14 mg\/dl) and after 2 months of treatment (7.74 mg\/dl),\n P<\/jats:italic>\n -value = 0.001. Uric acid levels \u22657 mg\/dl were significantly associated with arthralgia (\n P<\/jats:italic>\n -value = 0.017; odds ratio 14.00; 95% confidence interval 1.25\u2013156.61). Based on the Naranjo algorithm, those with hyperuricemia, eight and four patients had a total score of 7 and 8, respectively, which are classified as probable.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Uric acid levels significantly increased during the intensive phase. Pulmonary TB patients with hyperuricemia are a risk factor for arthralgia.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_178_23","type":"journal-article","created":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T16:00:59Z","timestamp":1726416059000},"page":"282-287","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Pyrazinamide-induced Hyperuricemia in Pulmonary Tuberculosis Patients"],"prefix":"10.4103","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1218-4372","authenticated-orcid":false,"given":"Oki Nugraha","family":"Putra","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Hang Tuah University, Surabaya, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Telly","family":"Purnamasari","sequence":"additional","affiliation":[{"name":"BRIN (Badan Riset dan Inovasi Nasional), Cibinong, Bogor, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nindya Maskurisna","family":"Hamami","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Hang Tuah University, Surabaya, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"key":"R2-20241212","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4103\/ijmy.ijmy_210_22","article-title":"Identification of Mycobacterium tuberculosis in pulmonary and extrapulmonary specimens of Iranian hospitalized patients during 2017-2021","volume":"12","author":"Salehi","year":"2023","journal-title":"Int J Mycobacteriol"},{"key":"R4-20241212","doi-asserted-by":"crossref","first-page":"e1003566","DOI":"10.1371\/journal.pmed.1003566","article-title":"Dynamics of sputum conversion during effective tuberculosis treatment: A systematic review and meta-analysis","volume":"18","author":"Calderwood","year":"2021","journal-title":"PLoS Med"},{"key":"R5-20241212","doi-asserted-by":"crossref","first-page":"e0281097","DOI":"10.1371\/journal.pone.0281097","article-title":"Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa","volume":"18","author":"Pietersen","year":"2023","journal-title":"PLoS One"},{"key":"R6-20241212","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.tips.2019.10.005","article-title":"Pharmacological and molecular mechanisms behind the sterilizing activity of pyrazinamide","volume":"40","author":"Gopal","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"R7-20241212","doi-asserted-by":"crossref","first-page":"e20180254","DOI":"10.1590\/1806-3713\/e20180254","article-title":"Serum pyrazinamide concentrations in patients with pulmonary tuberculosis","volume":"45","author":"Lucena","year":"2019","journal-title":"J Bras Pneumol"},{"key":"R8-20241212","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/1756-185X.13697","article-title":"Clinical features and risk factors for gout attacks during anti-tuberculosis treatment: A case-control study in South Korea","volume":"22","author":"Ha","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"R9-20241212","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/ijmy.ijmy_161_17","article-title":"Uric acid levels in patients on antituberculosis drugs in the Southwest region of Cameroon","volume":"7","author":"Thumamo","year":"2018","journal-title":"Int J Mycobacteriol"},{"key":"R10-20241212","first-page":"324","article-title":"Incidence of hyperuricemia and gouty arthritis in patients taking pyrazinamide for the treatment of tuberculosis","volume":"25","author":"Chandra","year":"2021","journal-title":"Ann Rom Soc Cell Biol"},{"key":"R11-20241212","doi-asserted-by":"crossref","first-page":"e0245368","DOI":"10.1371\/journal.pone.0245368","article-title":"Utilization of the Naranjo scale to evaluate adverse drug reactions at a free-standing children\u2019s hospital","volume":"16","author":"Murali","year":"2021","journal-title":"PLoS One"},{"key":"R12-20241212","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.3390\/jcm9124082","article-title":"Changes in nutritional status in pulmonary tuberculosis: Longitudinal changes in BMI according to acid-fast bacilli smear positivity","volume":"9","author":"Ko","year":"2020","journal-title":"J Clin Med"},{"key":"R13-20241212","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/1995-7645.372289","article-title":"Early efficacy of individual regimens containing bedaquiline in patients with drug resistant tuberculosis","volume":"16","author":"Putra","year":"2023","journal-title":"Asian Pac J Trop Med"},{"key":"R14-20241212","first-page":"241","article-title":"Baseline glycated hemoglobin and potassium level correlated with pretreatment QT-corrected interval among patients with diabetic drug-resistant tuberculosis","volume":"12","author":"Putra","year":"2023","journal-title":"Int J Mycobacteriol"},{"key":"R15-20241212","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.1093\/cid\/ciaa054","article-title":"Impact of diabetes and low body mass index on tuberculosis treatment outcomes","volume":"71","author":"Kornfeld","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R16-20241212","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4103\/ijmy.ijmy_154_22","article-title":"Pulmonary tuberculosis and diabetes mellitus: Clinical profile and outcomes","volume":"11","author":"George","year":"2022","journal-title":"Int J Mycobacteriol"},{"key":"R17-20241212","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12902-021-00779-6","article-title":"The association of glycemic level and prevalence of tuberculosis: A meta-analysis","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"R18-20241212","first-page":"679","article-title":"Drug-induced hyperuricaemia and gout","volume":"56","author":"Ben","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R19-20241212","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.nefroe.2022.05.007","article-title":"Gout associated with reduced renal excretion of uric acid. Renal tubular disorder that nephrologists do not treat","volume":"42","author":"Garc\u00eda-Nieto","year":"2022","journal-title":"Nefrologia (Engl Ed)"},{"key":"R20-20241212","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12879-019-4010-7","article-title":"Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease","volume":"19","author":"Saito","year":"2019","journal-title":"BMC Infect Dis"},{"key":"R21-20241212","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/antibiotics10080909","article-title":"Activity of pyrazinamide against Mycobacterium tuberculosis at neutral pH in PZA-S1 minimal medium","volume":"10","author":"Shi","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"R22-20241212","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3390\/pharmaceutics13060899","article-title":"Modulation of urate transport by drugs","volume":"13","author":"T\u00e1trai","year":"2021","journal-title":"Pharmaceutics"},{"key":"R23-20241212","first-page":"154","article-title":"Hyperuricemia and arthralgia during pyrazinamide therapy in patients with pulmonary tuberculosis","volume":"22","author":"Inayat","year":"2016","journal-title":"Pak J Chest Med"},{"key":"R24-20241212","doi-asserted-by":"crossref","first-page":"526","DOI":"10.18203\/2320-6012.ijrms20220304","article-title":"Pyrazinamide-induced acute gouty arthritis: A case report","volume":"10","author":"Emorinken","year":"2022","journal-title":"Int J Res Med Sci"},{"key":"R25-20241212","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4103\/0253-7613.190729","article-title":"A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients","volume":"48","author":"Pichholiya","year":"2016","journal-title":"Indian J Pharmacol"},{"key":"R26-20241212","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijantimicag.2019.06.010","article-title":"Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment","volume":"54","author":"Stemkens","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"R27-20241212","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1183\/13993003.02013-2020","article-title":"Optimising pyrazinamide for the treatment of tuberculosis","volume":"58","author":"Zhang","year":"2021","journal-title":"Eur Respir J"},{"key":"R28-20241212","doi-asserted-by":"crossref","first-page":"12394","DOI":"10.3390\/ijms222212394","article-title":"Uric acid in inflammation and the pathogenesis of atherosclerosis","volume":"22","author":"Kimura","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R29-20241212","doi-asserted-by":"crossref","first-page":"e0236109","DOI":"10.1371\/journal.pone.0236109","article-title":"The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis","volume":"15","author":"Kwon","year":"2020","journal-title":"PLoS One"},{"key":"R30-20241212","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5530\/ijopp.15.1.10","article-title":"Pyrazinamide-induced polyarthralgia and myalgia in a case of stable chronic kidney disease","volume":"15","author":"Panda","year":"2022","journal-title":"Indian J Pharm Pract"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_178_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:40:33Z","timestamp":1787773233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_178_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_178_23","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-05-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}